Pfizer Shares Updated Lung Cancer Bispecifics Data at ASCO

At the ASCO Annual Meeting, updated Phase 2 data for Pfizer's bispecific antibody PF-08634404 demonstrated activity as monotherapy in first-line PD-L1-expressing non-small cell lung cancer. The updated Phase 2 data offers a new therapeutic avenue for patients battling this aggressive disease, potentially expanding treatment options beyond existing standards. Pfizer also showcased its broad oncology portfolio, presenting more than 50 company-sponsored abstracts, including 11 oral presentations, at the conference, according to Pfizer.

The oncology market is saturated with treatments for non-small cell lung cancer (NSCLC), yet PF-08634404 is showing promising activity. Its novel bispecific mechanism and rapid advancement differentiate it from existing agents. Its novel bispecific mechanism and rapid advancement suggest a potent standalone effect, rather than requiring combination therapy, which is often the case for new oncology agents in saturated markets.

Pfizer is strategically advancing a differentiated bispecific antibody that could carve out a significant market share in NSCLC and other difficult-to-treat cancers, potentially reshaping future treatment guidelines and strengthening its oncology portfolio.

What are Pfizer's next steps for bispecifics?

• Pfizer revealed plans for a pivotal trial of PF-08634404 in extensive stage small cell lung cancer (SCLC), according to Oncology Pipeline.
• The Phase 2/3 study for PF-08634404 is already post-enrollment, indicating rapid progression towards regulatory submission, according to Oncology Pipeline.
• A seven-year update from the pivotal Phase 3 CROWN study supports LORBRENA ®(lorlatinib) as a first-line treatment for ALK-positive metastatic non-small cell lung cancer (NSCLC), as reported by Pfizer.
• A late-breaking presentation of progression-free survival (PFS) and overall survival (OS) data from Cohort 3 of the BREAKWATER* trial, evaluating BRAFTOVI ®(encorafenib) in combination with cetuximab and FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer, was also presented by Pfizer.

PF-08634404's dual targeting of PD-1 and VEGF as a monotherapy in first-line NSCLC suggests a potential to overcome resistance mechanisms. PF-08634404's dual targeting of PD-1 and VEGF may enhance efficacy beyond single-target agents. PF-08634404's dual targeting offers a distinct advantage in a crowded oncology market.